Insider Trading: Ex-Ariad Staffers Charged With Using FDA Info On Iclusig
Executive Summary
Former directors of pharmacovigilance and risk management agree to pay disgorgements and civil penalties in SEC complaints charging them with trading in Ariad stock in advance of FDA announcements about the leukemia drug Iclusig.